Me. Rev. Stat. » Title 22
Maine Revised Statutes

Me. Rev. Stat. tit. 22, § 2698-A (2026)

Marketing costs

✓ current as of May 2026
Find cases: SyfertCases citing this section ME-LEGlegislature.maine.gov JustiaTitle on Justia CornellLII Search CasesGoogle Scholar
(REPEALED)
SECTION HISTORY
RR 2003, c. 1, §17 (RAL). RR 2003, c. 1, §18 (AFF). PL 2003, c. 688, §C8 (AMD). PL 2005, c. 286, §§1,2 (AMD). PL 2011, c. 461, §3 (RP).
The Revisor's Office cannot provide legal advice or interpretation of Maine law to the public.
If you need legal advice, please consult a qualified attorney.
Notes of Decisions
Cited in 2 cases, 2008–2008 · leading case: IMS Health Inc. v. Ayotte, 550 F.3d 42 (1st Cir. 2008).
Sort: Relevance Newest Treatment
IMS Health Inc. v. Ayotte, 550 F.3d 42 (1st Cir. 2008). · cites it 2× “; see Me. Rev.Stat. Ann. tit. 22, § 2698-A (2004) (disclosure); Minn.”
IMS Health Corp. v. Rowe, 532 F. Supp. 2d 153 (D. Me. 2008). “22 M.R.S.A. § 2698-A. Maine law mandates that pharmaceutical companies make a quarterly report of their pharmaceutical pricing criteria for each prescription drug dispensed in the state.”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.